

# The Nomination Committee's proposal regarding the Board of CellaVision AB for the 2021 Annual General Meeting

Ahead of the Annual General Meeting (AGM) 2021 the Nomination Committee of CellaVision AB proposes that the Board shall be composed of seven directors elected at the AGM, with no alternates, for the period until the next AGM.

The Nomination Committee proposes the current Board member Mikael Worning as Chairman of the Board and re-election of the Board members Anna Malm Bernsten, Christer Fåhraeus, Åsa Hedin, Niklas Prager, Jürgen Riedl, and Stefan Wolf. The Board member and current Chairman of the Board Sören Mellstig has declared that he is not available for re-election.

CellaVision's Nomination Committee for the 2021 AGM consists of Christer Fåhraeus and companies, (Chairman of the Nomination Committee), Nicklas Hansen, appointed by William Demant Invest A / S, Joel Eklund, appointed by Grenlunden CEVI AB, and Daniel Klint, appointed by SEB Investment funds. The Nomination Committee is convened by Sören Mellstig who participated as co-opted, but who is not part of the Nomination Committee.

"The Nomination Committee proposes Mikael Worning as the new Chairman of the Board of CellaVision. Mikael, who has been a Board member of CellaVision for one year, has extensive experience in medical technology, not least from his many years at Radiometer and Oticon. Most recently he came from a role as CEO of Demant in the USA, where he led the growth of Demant to an annual turnover of more than SEK 5 billion. His previous assignments and insights into CellaVision will bring valuable perspectives for CellaVision's development and strategic work ", says Christer Fåhraeus, Chairman of the Nomination Committee and founder of CellaVision.

The Nomination Committee's other proposals for the AGM on April 29, 2021 and the statement on the proposed Board will be available on the company's website [www.cellavision.com](http://www.cellavision.com) in connection with the announcement of the notice convening the AGM.

## For more information, please contact:

Christer Fåhraeus, Chairman of the Nomination Committee, CellaVision AB  
Tel: +46 (0) 705-60 90 00 | Email: [cf@eqlpharma.com](mailto:cf@eqlpharma.com)

## Contacts

---

Maria Morin  
VP HR & Corporate Communications  
Direct: +46 46 460 16 52  
Mobile: +46 709 92 62 28  
Email: [maria.morin@cellavision.com](mailto:maria.morin@cellavision.com)

## About Us

---

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 18 local market support organizations covering more than 40 countries. In 2020, sales were SEK 471 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at [www.cellavision.com](http://www.cellavision.com)

## Attachments

---

[The Nomination Committee's proposal regarding the Board of CellaVision AB for the 2021 Annual General Meeting](#)